tirzepatide + insulin glargine

Tirzepatide + insulin glargine is a combination therapeutic regimen consisting of tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, and insulin glargine, a long-acting basal insulin analog. Developed by Eli Lilly, this combination is primarily investigated for the management of type 2 diabetes mellitus in patients whose glycemic levels are inadequately controlled by basal insulin alone. Tirzepatide acts as a "twincretin," mimicking the effects of both endogenous incretin hormones to enhance glucose-dependent insulin secretion, improve insulin sensitivity, and reduce food intake. Insulin glargine provides a consistent, peakless concentration of insulin over 24 hours to regulate fasting blood glucose. Clinical data from the SURPASS-5 trial demonstrated that adding tirzepatide to titrated insulin glargine resulted in significant improvements in HbA1c levels and body weight compared to placebo plus insulin glargine, offering a potent option for patients requiring intensified therapy.

Brand names

Mounjaro + LantusZepbound + LantusMounjaro + BasaglarZepbound + BasaglarMounjaro + ToujeoZepbound + Toujeo

Other names

tirzepatide plus insulin glarginetirzepatide and insulin glarginetirzepatide + glargine